Surgical Pathology Clinics

Urothelial Carcinoma

Update on Staging and Reporting, and Pathologic Changes Following Neoadjuvant Chemotherapies
  • Manju Aron
    Corresponding author. 1500 San Pablo Street, HC4, Room 2409, Los Angeles, CA 90033-5313.
    Department of Pathology, Keck School of Medicine, University of Southern California

    Department of Urology, Keck School of Medicine, University of Southern California
    Search for articles by this author
  • Ming Zhou
    Department of Anatomic and Clinical Pathology, Tufts University School of Medicine and Tufts Medical Center, 800 Washington St., Box 802, Boston, MA 02111
    Search for articles by this author
Published:October 12, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amin M.B.
        • Edge S.B.
        • Greene F.L.
        • et al.
        AJCC cancer staging manual.
        Springer, New York, NY2017
        • Paner G.P.
        • Montironi R.
        • Amin M.B.
        Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances.
        Adv Anat Pathol. 2017; 24: 113-127
        • Paner G.P.
        • Stadler W.M.
        • Hansel D.E.
        • et al.
        Updates in the 8th edition of the tumor-node-metastasis staging classification for urologic cancers.
        Eur Urol. 2018; 73: 560-569
        • Bella A.J.
        • Stitt L.W.
        • Chin J.L.
        • et al.
        The prognostic significance of metastatic perivesical lymph nodes identified in radical cystectomy specimens for transitional cell carcinoma off the bladder.
        J Urol. 2003; 170: 2253-2257
        • Hu B.
        • Satkunasivam R.
        • Schuckman A.
        • et al.
        Significance of perivesical lymph node in radical cystectomy for bladder cancer.
        Urol Oncol. 2014; 32: 1158-1165
        • von der Maase H.
        • Sengelov L.
        • Robert J.T.
        • et al.
        Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
        J Clin Oncol. 2005; 23: 4602-4608
        • Apolo A.B.
        • Ostrovnaya I.
        • Halabi S.
        • et al.
        Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
        J Natl Cancer Inst. 2013; 105: 499-503
        • Galsky M.D.
        • Moshier E.
        • Krege S.
        • et al.
        Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin- based chemotherapy.
        Cancer. 2013; 119: 3012-3019
        • Babjuk M.
        • Burger M.
        • Comperat E.M.
        • et al.
        European Association of Urology guidelines on nonmuscle invasive bladder cancer (Ta/T1 and carcinoma in situ)- 2019 update.
        Eur Urol. 2019; 76: 639-657
        • Klassen Z.
        • Kamat A.M.
        • Kassouf W.
        • et al.
        Treatment strategy for newly diagnosed T1 high grade bladder urothelial carcinoma: new insights and updated recommendations.
        Eur Urol. 2018; 74: 597-608
        • Parizi M.
        • Enikeev D.
        • Glybochko P.V.
        • et al.
        Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
        World J Urol. 2020; 38: 1437-1449
        • Younes M.
        • Sussman J.
        • True L.D.
        The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma off the urinary bladder.
        Cancer. 1990; 66: 543-548
        • Rouperet M.
        • Seisen T.
        • Comperat E.
        • et al.
        Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
        J Urol. 2013; 189: 2069-2076
        • Fransen van de Putte E.E.
        • Behrendt M.A.
        • Pigot G.L.S.
        • et al.
        Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder.
        Curr Opin Urol. 2015; 25: 427-435
        • Leivo M.Z.
        • Sahoo D.
        • Hamilton Z.
        • et al.
        Analysis of T1 bladder cancer on biopsy and transurethral resection specimens: comparison and ranking of T1 quantification approaches to predict progression to muscularis propria invasion.
        Am J Surg Pathol. 2018; 42: e1-e10
        • DE Marco V.
        • Cerruto M.A.
        • D’Elia C.
        • et al.
        Prognostic role of sub staging in T1 G 3 transitional cell carcinoma of the urinary bladder.
        Mol Clin Oncol. 2014; 2: 575-580
        • Brimo F.
        • Wu C.
        • Zeizafoun N.
        • et al.
        Prognostic factors in D1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosae invasion.
        Hum Pathol. 2013; 44: 95-102
        • Colombo R.
        • Hurle E.
        • Moschini M.
        • et al.
        Feasibility and clinical roles of different sub staging systems at 1st and 2nd transurethral resection in patients with T1 high-grade bladder cancer.
        Eur Urol Focus. 2018; 4: 87-93
        • Lee J.Y.
        • Joo H.J.
        • Cho D.S.
        • et al.
        Prognostic significance of sub staging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder.
        Korean J Urol. 2012; 53: 317-323
        • Olsson H.
        • Hultman P.
        • Rosell J.
        • et al.
        Population based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumors.
        Scand J Urol. 2013; 47: 188-195
        • Patriarca C.
        • Hurle R.
        • Moschini M.
        • et al.
        Usefulness of PT1 sub staging in papillary urothelial bladder carcinoma.
        Diagn Pathol. 2016; 11: 6
        • Patschan O.
        • Sjodahl G.
        • Chebil G.
        • et al.
        A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma.
        Eur Urol. 2015; 68: 824-832
        • Paner G.P.
        • Ro J.Y.
        • Wojcik E.M.
        • et al.
        Further characterization of the muscle layers and laminar propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma.
        Am J Surg Pathol. 2007; 31: 1420-1429
        • Angulo J.Z.
        • Lopez J.I.
        • Grignon D.J.
        • et al.
        Muscularis mucosa differentiates two populations with different prognosis stage T1 bladder cancer.
        Urology. 1995; 45: 47-53
        • Sozen S.
        • Akbal C.
        • Sokmensuer C.
        • et al.
        Microstaging of pT1 transition cell carcinoma of the bladder. Does it really differentiate two populations with different prognosis? (pT1 subcategory).
        Urol Int. 2002; 69: 200-206
        • Cheng L.
        • Jones T.D.
        • McCarthy R.P.
        • et al.
        Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.
        Am J Pathol. 2005; 166: 1533-1539
        • van Rhijn B.W.G.
        • van der Kwast T.H.
        • Alkhateeb S.S.
        • et al.
        A new and highly prognostic system to discern T1 bladder cancer substage.
        Eur Urol. 2012; 61: 378-384
        • Hu Z.
        • Mudaliar K.
        • Quek M.L.
        • et al.
        Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
        Ann Diagn Pathol. 2014; 18: 49-52
        • Otto W.
        • van Rhijn B.W.
        • Breyer J.
        • et al.
        Infiltrative lamina propria invasion pattern as an independent predictor for cancer- specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer.
        Int J Urol. 2018; 25: 442-449
        • van der Aa M.N.
        • van Leenders G.J.
        • Steyerberg E.W.
        • et al.
        A new system for substaging PT1 papillary bladder cancer: prognostic evaluation.
        Hum Pathol. 2005; 36: 981-986
        • Bertz S.
        • Denzinger S.
        • Otto W.
        • et al.
        Substaging by estimating the size of invasive tumor can improve risk stratification in pT1 urothelial bladder cancer evaluation of a large hospital- based single- center series.
        Histopathology. 2011; 59: 722-732
        • Chang W.C.
        • Chang Y.H.
        • Pan C.C.
        Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection.
        Am J Surg Pathol. 2012; 36: 454-461
        • Nishiyama N.
        • Kitamura H.
        • Maeda T.
        • et al.
        Clinical pathological analysis of patients with non- muscle- invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
        Jpn J Clin Oncol. 2013; 43: 1124-1131
        • Budina A.
        • Farahani S.J.
        • Lal P.
        • et al.
        Subcategorization of T1 bladder cancer on biopsy and transurethral specimens for predicting progression.
        Arch Pathol Lab Med. 2021; (Online ahead of print)
        • Lawless M.
        • Gulati R.
        • Tretiakova M.
        Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
        Histopathology. 2017; 71: 406-414
        • Donat S.M.
        • Genega E.M.
        • Herr H.W.
        • et al.
        Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance.
        J Urol. 2001; 165: 1117-1120
        • Esrig D.
        • Freeman J.A.
        • Elmajian D.A.
        • et al.
        Transitional cell carcinoma involving the prostate with the proposed staging classification for stromal invasion.
        J Urol. 1996; 15: 1071-1076
        • Montironi R.
        • Cheng L.
        • Mazzucchelli R.
        • et al.
        Critical evaluation of the prostate from cystoprostatectomy for bladder cancer: insights from a complete sampling with the whole mount technique.
        Eur Urol. 2009; 55: 1305-1309
        • Knoedler J.J.
        • Boorjian S.A.
        • Tollefson K.
        • et al.
        Urothelial carcinoma involving the prostate: association of revised tumor stage and coexistent bladder cancer with survival after radical cystectomy.
        BJU Int. 2014; 1114: 832-836
        • Njinou Ngninkeu B.
        • Lorge F.
        • Moulin P.
        • et al.
        Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases.
        J Urol. 2003; 169: 149-152
        • Ayyathurai R.
        • Gomez P.
        • Luongo T.
        • et al.
        Prostatic involvement by urothelial carcinoma bladder: clinicopathological features and outcome after radical cystectomy.
        BJU Int. 2007; 100: 1021-1025
        • Vallo S.
        • Gilfrich C.
        • Burger M.
        • et al.
        Comparative analysis of the effect of prostatic invasion patterns on cancer- specific mortality after radical cystectomy in pT4 a urothelial carcinoma of the bladder.
        Urol Oncol. 2016; 34: 432.e1-432.e8
        • Patel A.R.
        • Cohn J.A.
        • Abd El Latif A.
        • et al.
        Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma.
        J Urol. 2013; 189: 53-58
        • Daneshmand S.
        • Stein J.P.
        • Lesser T.
        • et al.
        Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder.
        J Urol. 2004; 172: 81-84
        • Volkmer B.G.
        • Kufer R.
        • Maier S.
        • et al.
        Outcome in patients with seminal vesicle invasion after radical cystectomy.
        J Urol. 2003; 169: 1299-1302
        • May M.
        • Brookman-May S.
        • Burger M.
        • et al.
        Concomitant seminal vesicle invasion in pT4a urothelial carcinoma of the bladder with contiguous prostatic infiltration is an adverse prognosticator for cancer- specific survival after radical cystectomy.
        Ann Surg Oncol. 2014; 21: 4034-4040
        • You D.
        • Kim S.C.
        • Jeong I.G.
        • et al.
        Urothelial carcinoma of the bladder with seminal vesicle invasion: prognostic significance.
        BJU Int. 2010; 106: 1657-1661
        • Chen M.E.
        • Pisters L.L.
        • Malpica A.
        • et al.
        Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from MD Anderson Cancer Center.
        J Urol. 1997; 157: 2120-2123
        • Salem H.
        • El-Mazny A.
        Clinicopathologic study of gynecologic organ involvement at radical cystectomy for bladder cancer.
        Int J Gynecol Obstet. 2011; 115: 188-190
        • Varkaris I.M.
        • Pinggera G.
        • Antoniou N.
        • et al.
        Pathological review of internal genitalia after anterior exenteration for bladder cancer in women. Evaluating risk factors for female organ involvement.
        Int Urol Nephrol. 2007; 39: 1015-1021
        • Ali-El-Dein B.
        • Abdel-Latif M.
        • Mosbah A.
        • et al.
        Secondary malignant involvement of gynecological organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely?.
        J Urol. 2004; 172: 885-887
        • Groutz A.
        • Gillon G.
        • Konichezky M.
        • et al.
        involvement of internal genitalia in female patients undergoing radical cystectomy for bladder cancer: a clinico pathological study of 37 cases.
        Int J Gynecol Cancer. 1999; 9: 302-306
        • Ghoneim M.A.
        • Abdel-Latif M.
        • el-Mekresh M.
        • et al.
        Radical cystectomy for carcinoma the bladder: 2,720 consecutive cases five years later.
        J Urol. 2008; 180: 121-127
        • Tilki D.
        • Reich O.
        • Svatek R.S.
        • et al.
        Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
        J Urol. 2010; 183: 1757-1763
        • Aziz A.
        • Shariat S.F.
        • Roghmann F.
        • et al.
        Prediction of cancer- specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
        BJU Int. 2016; 117: 272-279
        • May M.
        • Bastian P.J.
        • Brookman-May S.
        • et al.
        Gender specific differences in cancer- specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
        Urol Oncol. 2013; 31: 1141-1147
        • Magers M.J.
        • Lopez-Beltran A.
        • Montironi R.
        • et al.
        Staging of bladder cancer.
        Histopathology. 2019; 74: 112-134
        • Hansel D.E.
        • Paner G.P.
        • Nese N.
        • et al.
        Limited smoothelin expression within the muscularis mucosa: validation in bladder diverticula.
        Hum Pathol. 2011; 42: 1770-1776
        • Goliajinin D.
        • Yossepowitch O.
        • Beck S.D.
        • et al.
        Carcinoma in a bladder diverticulum: presentation and treatment outcome.
        J Urol. 2003; 170: 1761-1764
        • Tamas E.F.
        • Stephenson A.J.
        • Campbell S.C.
        • et al.
        Histological features and clinical outcomes in 71 cases of bladder diverticula.
        Arch Pathol Lab Med. 2009; 133: 791-796
        • Hu B.
        • Satkunasivam R.
        • Schuckman A.
        • et al.
        Urothelial carcinoma in bladder diverticula: outcomes after radical cystectomy.
        World J Urol. 2015; 33: 1397-1402
        • Cheng L.
        • Montironi R.
        • Davidson D.D.
        • et al.
        Staging and reporting of urothelial cancers of the urinary bladder.
        Mod Pathol. 2009; 22: 70-95
        • Comperat E.
        • Egevad L.
        • Lopez-Beltran A.
        • et al.
        An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heat maps.
        Histopathology. 2013; 63: 756-766
        • Beltran A.L.
        • Cheng L.
        • Monitroni R.
        • et al.
        Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder.
        Virchows Arch. 2014; 465: 199-205
        • Volmar K.E.
        • Chan T.Y.
        • DeMarzo A.M.
        • et al.
        Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.
        Am J Surg Pathol. 2003; 27: 1243-1252
        • Wasco M.J.
        • Diagnault S.
        • Bradley D.
        • et al.
        Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases.
        Hum Pathol. 2010; 41: 163-171
        • Ananthanarayan V.
        • Pan Y.
        • Tretiakova M.
        • et al.
        Influence of histologic criteria and confounding factors in staging of equivocal cases for microscopic perivesical invasion (pT3a ): an interobserver study among genitourinary pathologists.
        Am J Surg Pathol. 2014; 38: 167-175
        • Tretter E.M.
        • Ebel J.J.
        • Pohar K.S.
        • et al.
        Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?.
        Hum Pathol. 2017; 61: 190-198
        • Aron M.
        • Park S.
        • Lowenthal B.M.
        • et al.
        Primary female urethral carcinoma proposed staging modifications based on assessment of female urethra Histology and analysis of a large series of female urethral carcinomas.
        Am J Surg Pathol. 2020; 44: 1591-1592
        • Vashistha V.
        • Shabsigh A.
        • Zynger D.L.
        Utility and diagnostic accuracy of uretroscopic biopsy in upper tract urothelial carcinoma.
        Arch Pathol Lab Med. 2013; 137: 400-407
        • El-Hakim A.
        • Weiss G.H.
        • Lee B.R.
        • et al.
        Correlation of ureteroscopic appearance with histologic grade of upper tract transitional cell carcinoma.
        Urology. 2004; 63: 647-650
        • Katayama S.
        • Mori K.
        • Schuettfort V.M.
        • et al.
        Accuracy and clinical utility offer tumor grade- and stage- based predictive model in localized upper tract urothelial carcinoma.
        Eur Urol Focus. 2021; S2405-4569 (Online ahead of print): 00154-00161
        • van der Poel H.G.
        • Antonini N.
        • van Tinteren H.
        • et al.
        Upper urinary tract cancer: location is correlated with prognosis.
        Eur Urol. 2005; 48: 438-444
        • Kikuchi E.
        • Marguilis V.
        • Karakiewicz P.I.
        • et al.
        Lymphovascular invasion predicts clinical outcomes in patients with node- negative upper tract urothelial carcinoma.
        J Clin Oncol. 2009; 27: 612-618
        • Raman J.D.
        • Ng C.K.
        • Scherr D.S.
        • et al.
        Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
        Eur Urol. 2010; 57: 1072-1079
        • Cho K.S.
        • Cho N.H.
        • Park S.Y.
        • et al.
        Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma.
        J Korean Med Sci. 2008; 23: 434-438
        • Park J.
        • Ha S.H.
        • Min G.E.
        • et al.
        The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival.
        J Urol. 2009; 182: 894-899
        • Park J.
        • Park S.
        • Song C.
        • et al.
        Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma.
        World J Urol. 2014; 32: 157-163
        • Wu D.
        • Lee C.T.
        • Zynger D.L.
        • et al.
        Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival.
        Hum Pathol. 2022; 125: 79-86
      1. Cancer protocol templates (Internet). College of American Pathologists.
        • Comperat E.
        • Srigley J.R.
        • Brimo F.
        • et al.
        Dataset for the reporting of carcinoma of the bladder- cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).
        Virchows Arch. 2020; 476: 521-534
        • Varma M.
        • Srigley J.R.
        • Brimo F.
        • et al.
        Data set for the reporting of urinary tract carcinoma- biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).
        Mod Pathol. 2020; 33: 700-712
        • Lopez-Beltran A.
        • Luque R.J.
        • Mazzucchelli R.
        • et al.
        Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.
        J Clin Pathol. 2002; 55: 641-647
        • Chan T.Y.
        • Epstein J.I.
        Radiation or chemotherapy cystitis with “pseudocarcinomatous” features.
        Am J Surg Pathol. 2004; 28: 909-913
        • Lopez J.I.
        • Schiavo-Lena M.
        • Corominas-Cishek A.
        • et al.
        Nephrogenic adenoma of the urinary tract: clinical, histological and immunohistochemical characteristics.
        Virchows Arch. 2013; 463: 819-825
        • Pina-Oviedo S.
        • Shen S.S.
        • Truong L.D.
        • et al.
        Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX 8 immunohistochemistry.
        Mod Pathol. 2013; 26: 792-798
        • Williamson S.R.
        • Al-Ahmadie H.A.
        • Cheng L.
        • et al.
        Invasive urothelial carcinoma.
        in: WHO classification of Tumors editorial Board. Urinary and male genital tumors. 5th edition. International Agency for Research on Cancer, Lyon(France)2022: 157
        • Meeks J.J.
        • Al-Ahmadie H.
        • Faltas B.M.
        • et al.
        Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.
        Nat Rev Urol. 2020; 17: 259-270
        • Hansel D.E.
        • Amin M.B.
        • Comperat E.
        • et al.
        A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.
        Eur Urol. 2013; 623: 321-332
        • Wasco M.J.
        • Daignault S.
        • Zhang Y.
        • et al.
        Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.
        Urology. 2007; 70: 69-74
        • Kamoun A.
        • de Reynies A.
        • Allory Y.
        • et al.
        A consensus molecular classification of muscle- invasive bladder cancer.
        Eur Urol. 2020; 77: 420-433
        • Kim S.P.
        • Frank I.
        • Cheville J.C.
        • et al.
        The impact of squamous and glandular differentiation and survival after radical cystectomy for urothelial carcinoma.
        J Urol. 2012; 188: 405-409
        • Willis D.L.
        • Flaig T.W.
        • Hansel D.E.
        • et al.
        Micropapillary bladder cancer: current treatment patterns and review of the literature.
        Urol Oncol. 2014; 32: 826-832
        • Bertz S.
        • Wach S.
        • Taubert H.
        • et al.
        Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
        Virchows Arch. 2016; 469: 339-344
        • Meeks J.J.
        • Taylor J.M.
        • Matsushita K.
        • et al.
        Pathologic response to neoadjuvant chemotherapy for muscle- invasive micropapillary bladder cancer.
        BJU Int. 2013; 111: 325-330
        • Sui W.
        • Matulay J.T.
        • James M.B.
        • et al.
        Micropapillary bladder cancer: insights from the National Cancer database.
        Bladder Cancer. 2016; 2: 415-423
        • Guo C.C.
        • Dhadhania V.
        • Zhang I.
        • et al.
        Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer.
        Eur Urol. 2016; 70: 611-620
        • Kaimaklioitis H.Z.
        • Monn M.F.
        • Cheng L.
        • et al.
        Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes.
        Urology. 2014; 83: 1112-1116
        • Dayyani F.
        • Czerniak B.A.
        • Sircar K.
        • et al.
        Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.
        J Urol. 2013; 189: 1656-1661
        • Comperat E.
        • McKenney J.K.
        • Hartmann A.
        • et al.
        Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases.
        Histopathology. 2017; 71: 703-710
        • Cox R.
        • Epstein J.I.
        Large nested variant: 23 cases mimicking von Brunn nests and inverted growth pattern of non invasive papillary urothelial carcinoma.
        Am J Surg Pathol. 2011; 35: 1337-1342
        • Linder B.J.
        • Frank I.
        • Cheville J.C.
        • et al.
        Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis.
        J Urol. 2013; 189: 1670-1675
        • Wayerer V.
        • Eckstein M.
        • Comperat E.
        • et al.
        The large nested variant of urothelial carcinoma (LUNC) is the prototype of an FGFR 3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype.
        Cancers (Basel). 2020; 12: 763
        • Pan C.C.
        • Chang Y.H.
        • Chen K.K.
        • et al.
        Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer- specific mortality of non-muscle- invasive urothelial tumors of the urinary bladder: a clinical pathologic study of 1515 cases.
        Am J Clin Pathol. 2010; 133: 788-795
        • Amin M.B.
        • Comperat E.
        • Epstein J.I.
        • et al.
        The Genitourinary Pathology Society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia.
        Adv Anat Pathol. 2021; 28: 179-195
        • Cheng L.
        • Neumann R.M.
        • Nehra A.
        • et al.
        Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.
        Cancer. 2000; 88: 163-170
        • Gofrit O.N.
        • Pizov G.
        • Shapiro A.
        • et al.
        Mixed high and low grade bladder tumors; are they clinically high or low grade?.
        J Urol. 2014; 191: 1693-1696
        • Comperat E.
        • Varinot J.
        • Moroch J.
        • et al.
        A practical guide to bladder cancer pathology.
        Nat Rev Urol. 2018; 15: 143-154
        • van Rhijn B.W.
        • Musquera M.
        • Liu L.
        • et al.
        Molecular and clinical support for a four tiered grading system for bladder cancer based on the WHO1973 and 2004 classifications.
        Mod Pathol. 2015; 28: 695-705
        • Eisenberg M.S.
        • Boorjian S.A.
        • Cheville J.C.
        • et al.
        The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer.
        J Urol. 2013; 190: 2005-2010
        • von Rundstedt F.C.
        • Mata D.A.
        • Groshen S.
        • et al.
        Significance of lymphovascular invasion in organ- confined, node- negative urothelial cancer of the bladder: data from the prospective p53 -MVAC trial.
        BJU Int. 2015; 116: 44-49
        • Cha E.K.
        • Shariat S.F.
        • Kormaksson M.
        • et al.
        Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
        Eur Urol. 2012; 61: 818-825
        • Hurel S.
        • Rouperat M.
        • Ouzzane A.
        • et al.
        Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
        BJU Int. 2013; 111: 1199-1207
        • Amin M.B.
        • Trpkov K.
        • Lopez-Beltran A.
        • et al.
        Best practices recommendations in the application of immunohistochemistry in bladder lesions: report from the International Society of Urologic Pathology consensus conference.
        Am J Surg Pathol. 2014; 38: e20-e34
        • Leissner J.
        • Hohenfaellner R.
        • Thuroff J.W.
        • et al.
        Lymphadenectomy in patients with transitional cell carcinoma of the unary bladder; significance for staging and prognosis.
        BJU Int. 2000; 85: 817-823
        • Herr H.W.
        • Bochner B.H.
        • Dalbangi G.
        • et al.
        Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.
        J Urol. 2002; 167: 1295-1298
        • Wright J.L.
        • Din D.W.
        • Porter M.P.
        The association between extended lymphadenectomy and survival among patients with lymph node metastasis undergoing radical cystectomy.
        Cancer. 2008; 112: 2401-2408
        • Parkash V.
        • Bifulco C.
        • Feinn R.
        • et al.
        To count and how to count that is the question: interobserver and intraobserver variability among pathologists in lymph node counting.
        Am J Clin Pathol. 2010; 134: 42-49
        • Prendeville S.
        • Berney D.M.
        • Bubendorf L.
        • et al.
        Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web- based survey by the European network of Europe pathology.
        Histopathology. 2019; 74: 844-852
        • Kimura S.
        • Mari A.
        • Foerster B.
        • et al.
        Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: systematic review and meta-analysis.
        J Urol. 2019; 201: 46-53
        • Laukhtina E.
        • Rajwa P.
        • Mori K.
        • et al.
        Accuracy of frozen section analysis of urethral and ureteral margins during radical cystectomy for bladder cancer: a systematic review and diagnostic meta analysis.
        Eur Urol Focus. 2021; S2405-4569: 00162-00170
        • Grossman H.B.
        • Natale R.B.
        • Tangen C.M.
        • et al.
        Neodjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
        N Engl J Med. 2003; 349: 859-866
        • Shariat S.F.
        • Krakiewicz P.I.
        • Palapattu G.S.
        • et al.
        Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
        J Urol. 2006; 176: 2414-2422
        • Stein J.P.
        • Lieskovsky G.
        • Cote R.
        • et al.
        Radical cystectomy in the treatment of invasive bladder cancer: long- term results in 1,054 patients.
        J Clin Oncol. 2001; 19: 666-675
        • Motterle G.
        • Andrews J.R.
        • Morlacco A.
        • et al.
        Predicting response to neoadjuvant chemotherapy in bladder cancer.
        Eur Urol Focus. 2020; 6: 642-649
        • Fleischmann A.
        • Thalmann G.N.
        • Perren A.
        • et al.
        Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
        Am J Surg Pathol. 2014; 38: 325-332
        • Mi H.
        • Bivalacqua T.J.
        • Kates M.
        • et al.
        Predictive models of response to neoadjuvant chemotherapy in muscle- invasive bladder cancer using nuclear morphology and tissue architecture.
        Cell Rep Med. 2021; 2: 100382
        • Pokuri V.K.
        • Syed J.R.
        • Yang Z.
        • et al.
        Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle- invasive bladder carcinoma.
        Clin Genitourin Cancer. 2016; 14: e59-e65
        • Scosyrev E.
        • Ely B.W.
        • Messing E.M.
        • et al.
        Do mixed histological features affect survival benefit from neoadjuvant platinum- based combination chemotherapy in patients with locally advanced bladder cancer? Secondary analysis of Southwest Oncology Group- Directed Intergroup Study (S8710).
        BJU Int. 2011; 108: 693-699
        • Zargar-Shoshtari K.
        • Sverrisson E.F.
        • Sharma P.
        • et al.
        Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial cancer of the bladder with squamous or glandular differentiation.
        Clin Genitourin Cancer. 2016; 14: 82-88
        • Vetterlein M.W.
        • Wankowicz S.A.M.
        • Seisen T.
        • et al.
        Neoadjuvant chemotherapy prior to radical cystectomy for muscle- invasive bladder cancer with variant histology.
        Cancer. 2017; 123: 4346-4355
        • Abufaraj M.
        • Foerster B.
        • Schernhammer E.
        • et al.
        Micropapillary urothelial cancer of the bladder: a systematic review and meta- analysis of disease characteristics and treatment outcomes.
        Eur Urol. 2019; 75: 649-658
        • Diamantopoulos L.N.
        • Holt S.K.
        • Khaki A.R.
        • et al.
        Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from tertiary referral center and the surveillance, epidemiology, and end results (SEER) program.
        Clin Genitourin Cancer. 2021; 19: 144-154
        • Diamantopoulos L.N.
        • Khaki A.R.
        • Grivas P.
        • et al.
        Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.
        Bladder Cancer. 2020; 6: 71-81
        • Lynch S.P.
        • Shen Y.
        • Kamat A.
        • et al.
        Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long- term outcomes: results from a retrospective study at the MD Anderson Cancer Center.
        Eur Urol. 2013; 64: 307-313
        • Teo M.Y.
        • Guercio B.J.
        • Arora A.
        • et al.
        Long term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy.
        Clin Genitourin Cancer. 2022; S1558-7673 (Online ahead of print): 00110-00120
        • Wang H.J.
        • Solanki S.
        • Traboulsi S.
        • et al.
        Neoadjuvant chemotherapy- related histologic changes in radical cystectomy: assessment accuracy and prediction of response.
        Hum Pathol. 2016; 53: 35-40
        • Gronostaj K.
        • Czech A.K.
        • Fronczek J.
        • et al.
        The prognostic value of tumor regression grades combined with TNM classification in patients with muscle- invasive bladder cancer who underwent neoadjuvant chemotherapy followed by radical cystectomy.
        Clin Genitourin Cancer. 2019; 17: e1203-e1211
        • Voskuilen C.S.
        • Oo H.Z.
        • Genitsch V.
        • et al.
        Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle- invasive bladder carcinoma.
        Am J Surg Pathol. 2019; 43: 1600-1610
        • Brant A.
        • Kates M.
        • Chappidi M.R.
        • et al.
        Pathologic response in patients receiving neoadjuvant chemotherapy for muscle- invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?.
        Urol Oncol. 2017; 35: 34.e17-34.e25
        • Hansel D.E.
        • Amin M.B.
        • Comperat E.
        • et al.
        Contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.
        Eur Urol. 2013; 63: 321-332
        • Comperat E.
        • Oszwald A.
        • Wasinger G.
        • et al.
        Updated pathology reporting standards for bladder cancer: biopsies, transurethral resection and radical cystectomies.
        World J Urol. 2022; 40: 915-927